Transdermal Drug Delivery Systems Market Growth Analysis Research Report segmented by Product (Transdermal Patches and Semisolids), By Technology (Electric Current, Iontophoresis, Electroporation, Ultrasound, and Microporation), and Regional Forecast till 2030

5/5

( 17 votes )

Format :

Summary TOC Segmentation Methodology Infographics

Transdermal Drug Delivery Systems Market Snapshot

“The Transdermal Drug Delivery Systems Market to grow from USD 6.89 billion in 2023 to USD 14.72 Billion by 2030, at a CAGR of 4.2%.”

Transdermal drug delivery systems aim to improve the effectiveness of oral medications, which currently account for 74% of prescriptions. These systems, which are applied to the skin, deliver active medications directly into the bloodstream, offering benefits such as reduced hepatic metabolism, increased therapeutic efficacy, and stable drug plasma levels.

The adhesive is crucial for the system's safety, effectiveness, and quality, as it allows the medication to enter the bloodstream.

This analysis explores the advantages of topical drug delivery over standard oral and invasive methods. It discusses the effects of partitioning, solubility, chemical enhancers, and stratum corneum hydration on these methods.

The aim is to provide a platform for research and development of transdermal drug delivery dosage forms, focusing on recent developments in transdermal drug delivery systems.

Transdermal drug delivery offers advantages such as better efficacy-to-tolerability ratio, controlled release, and prevention of pre-systemic metabolism. It is particularly beneficial for patients with diabetes, as patches are particularly effective in delivering insulin.

The market for transdermal drug delivery systems is influenced by healthcare expenditures, product installations, technology impact, and regulatory changes, providing a comprehensive analysis of the market's growth, installed base, life line curves, and the impact of technology on healthcare.

Transdermal Drug Delivery Systems Market | Market Report Service

>>>Download Sample Report Now:https://marketreportservice.com/request-sample/transdermal-drug-delivery-systems-market-54712

Recent advances in transdermal drug delivery systems

Transdermal drug delivery system (TDDS) is a non-invasive alternative to traditional needle injections, offering low rejection rates, ease of administration, and patient convenience. It's particularly appealing in the pharmaceutical industry and the skin care sector, including cosmetics, as it avoids nonspecific drug distribution and local drug concentration buildup due to its primarily local administration approach.

Transdermal delivery of drugs is hindered by skin's physicochemical characteristics, prompting extensive research into solutions. This review outlines various TDDS approaches, their advantages and disadvantages, characterization techniques, and potential.

The high efficiency of these methods has been demonstrated through advancements in research, and they are expected to be utilized in various fields.

Segment Analysis

Transdermal patches and semisolids are product-based market segments for transdermal medication delivery systems. In 2022, transdermal patches dominated the market due to new technologies like mechanical arrays or microneedles.

However, semisolids are expected to grow at the fastest rate due to increasing production capacity using inorganic tactics.

The market for transdermal drug delivery systems is divided into five categories: electric current, iontophoresis, electroporation, ultrasound, and microporation.

The iontophoresis category, which dominated in 2022, is expected to grow rapidly from 2022-2030 due to technological advancements.

This technology enhances skin penetration and increases release rates for various transdermal drug delivery systems, despite poor absorption/permeation profiles.

Microporation is predicted to experience the fastest growth in the forecast period due to the increasing number of new products from industry players and the high market growth of mechanical array or microneedle transdermal drug delivery systems nearing the end of clinical trials.

Growth Drivers

Cardiovascular diseases (CVDs) are common causes of death worldwide, accounting for over 17.9 million deaths annually. Traditional medications like tablets and capsules are ineffective in managing these conditions. Innovative medication delivery strategies, such as transdermal drug delivery systems (TDDS), offer targeted administration to the affected areas and extended drug bioavailability. TDDS offers several benefits over oral medication administration in treating CVDs.

Transdermal patches, containing medication particles, are applied to the skin for cell engraftment. Cardiac patches are ideal for treating ischemic heart ailments, such as angina. They reduce oxygen demand by relaxing blood vessels and reducing heart strain. Recent developments in vascularized cardiac patches show promising results.

The prevalence of chronic diseases is on the rise.
The use of transdermal patches is on the rise.
Growing demand for non-invasive drug delivery system

Restraints

After the recommended use duration, topical patches, transdermal drug delivery systems (TDDS), and transmucosal drug delivery systems (TMDS) may retain 10-95% of the original medicine as a residual drug, posing a risk to patients' safety and their loved ones.

Unavoidable events from patients using TDDS can intensify or prolong the drug's pharmacological impact, and some children have died after accidentally coming into contact with abandoned TDDS.

The development of drug delivery systems is a costly endeavor.
Recalls of transdermal drug delivery systems and drug failure

Opportunities

The manufacturers are implementing strategic activities to achieve their goals.

Trends

The adoption of third-generation delivery systems is on the rise.

The demand for geriatric medications has surged due to population growth, leading to a rise in chronic illnesses like diabetes, arthritis, and heart disease. This has prompted increased R&D efforts to enhance medication efficacy and increased patient awareness about medication usage.

This has positively impacted the global CAGR of the transdermal drug delivery systems market, as these factors have led to a significant increase in the number of individuals with these chronic illnesses, which are the primary cause of death and disability.

Competitive Landscape of the Transdermal Drug Delivery Systems Market Analysis

Hisamitsu Pharmaceutical (Japan)
Mylan (US)
UCB (Belgium)
Novartis (Switzerland)
GlaxoSmithKline (UK)
Boehringer Ingelheim (Germany)
Johnson & Johnson (US)
Endo International (Ireland)
and Purdue Pharma (US).

New Developments in Transdermal Drug Delivery Systems Market

In October 2023, Novartis completed a 100% spin-off of Sandoz, its Generics and Biosimilars business, to create an independent company.

June 30, 2022 — Novartis acquires Kedalion Therapeutics and its innovative ocular delivery platform that could transform patient experience.

Novartis announced that it has acquired Kedalion Therapeutics and its AcuStream™ technology, an innovative device that may have the potential to facilitate precise dosing and accurate delivery of certain topical ophthalmic medications to the eye. The acquisition enhances the Novartis ophthalmics portfolio, advancing efforts to investigate transformative ophthalmic methods to address unmet patient needs in front-of-eye conditions.

In December 2022, Luye Pharma Group held an offline product launch conference in Shanghai, along with an online event, to announce the launch of Ruoxinlin (Toludesvenlafaxine hydrochloride extended-release tablets) in China. Ruoxinlin is China’s first class-1 innovative chemical drug independently developed for the treatment of major depressive disorder (MDD) through a local administration and protected by intellectual property rights. The drug provides a powerful new option for patients, bringing the treatment of MDD to a new level.

Feb 2020, GlaxoSmithKline announced that the FDA has approved Voltaren Arthritis Pain as an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults. With the FDA’s approval, Voltaren Arthritis Pain becomes the first and only prescription strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the United States.

Dec 2019, Hisamitsu Pharmaceutical Co., Inc. launched HARUROPI TAPE, transdermal, Parkinson’s disease treatment patch in Japan from December 17, 2019 following National Health Insurance (NHI) drug price listing on November 19, 2019.

Jul 2019, Luye Pharma Group has announced that the German Federal Institute for Drugs and Medical Devices has approved the marketing authorization of the company’s Rivastigmine once-a-day transdermal patch in a dosage of 13.3mg/24h. The high dosage strength comes in addition to two other dosage strengths already on the market, 4.6mg/24h and 9.5mg/24h, helping doctors provide more suitable dosages to patients in accordance with their needs.

Regional Analysis of Global Transdermal Drug Delivery Systems Industry

The North America transdermal medication delivery system market is projected to grow at a healthy pace through 2030, accounting for over 45% of the market's revenue in 2022, despite the increasing prevalence of unhealthy lifestyles and disease rates.

North America is expected to experience significant growth due to the repositioning of outdated medications and improvements in current drug formulations in the US and Canada.

The Asia Pacific region is expected to become the world market region with the highest income due to the increasing number of chronic illness patients in developed and developing nations, including China and India.

The global market for transdermal drug delivery systems is expected to grow moderately in Latin America, the Middle East, and Africa due to the presence of less established market participants in these regions.

Segments Covered in the Transdermal Drug Delivery Systems Market Report

Transdermal Drug Delivery Systems Market Segment by Product

Transdermal Patches
Semisolids

Transdermal Drug Delivery Systems Market Segment by Technology

Electric Current
Iontophoresis
Electroporation
Ultrasound
Microporation

Transdermal Drug Delivery Systems Market by Region

North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America

Frequently Asked Questions

What are some applications of Transdermal Drug Delivery Systems?

Transdermal medication administration involves applying it topically to the skin, which is then absorbed into the bloodstream, offering a simple and effective method for administering medications.

What is the expected growth rate of the Transdermal Drug Delivery Systems market over the next 7 years?

The Transdermal Drug Delivery Systems Market to grow from USD 6.89 billion in 2023 to USD 14.72 Billion by 2030, at a CAGR of 4.2%.

Who are the major players in the Transdermal Drug Delivery Systems market and what is their market share?

Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US), are prominent players operating and dominating in the market.

Who are the top 3 Transdermal Drug Delivery Systems Market Key Vendors?

Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), are key players in the Transdermal Drug Delivery Systems market.

Which geographical areas dominate the worldwide market for Transdermal Drug Delivery Systems?

North America region are emerging as the top regional markets for Transdermal Drug Delivery Systems solutions.

Base Year:2022

Historical Data:2018-2022

No of Pages:122

Select Licence Type

Single User

US$ 2499

Multi User

US$ 3499

Corporate User

US$ 4499

Only one user can access the report. It cannot be printed or shared. Delivery in online PDF.

US $ 2499

Multiple users can access the report. It cannot be printed or shared. Delivery in online PDF.

US $ 3499

The entire organization can use the report. It can be printed and shared. Delivery in PDF and Excel. Free update of the report after 1 year.

US $ 4499

Buy Now

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Phone:

Toll Free:

Email: sales@marketreportservice.com

Transdermal Drug Delivery Systems Market Growth Analysis Research Report segmented by Product (Transdermal Patches and Semisolids), By Technology (Electric Current, Iontophoresis, Electroporation, Ultrasound, and Microporation), and Regional Forecast till 2030

Select Licence Type

Need a Discount? Get in touch with us for special pricing

Connect with our sales team

Industry Verticals

Quick Links

Legal

Subscribe Us

Office Addresses